Explain how bcl-6 relates to this case

BCL-6 and Josh's Case

Based on Josh's clinical summary, BCL-6 is directly relevant to his current treatment approach:

BCL-6 Pathway Involvement

According to the document, Josh has BCL-6 pathway involvement identified in his follicular lymphoma. This molecular finding is significant because it represents a specific vulnerability in his cancer cells that can be targeted with specialized therapy.

Current Treatment Strategy

Josh is currently participating in a first-in-human BCL-6 degrader trial (as of November 2025). A degrader is a type of drug designed to break down (degrade) specific proteins—in this case, the BCL-6 protein that appears to be driving his lymphoma cells.

This represents a precision medicine approach: rather than using broad chemotherapy that affects many cells, this therapy targets a specific molecular feature of Josh's cancer.

Important Context

However, the document notes a critical challenge: Josh experienced disease progression after just 8 weeks on this BCL-6 degrader therapy. This means the cancer continued to grow despite targeting this pathway, suggesting his disease may be resistant to this particular approach.

Next Steps

The document indicates Josh has a biopsy scheduled for [date removed], which will likely help his medical team understand why the BCL-6 degrader didn't work and identify other potential treatment targets.

I'd recommend Josh discuss these biopsy results with his oncology team to explore what the molecular findings reveal about his cancer's behavior.